Literature DB >> 26662106

IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Xiaofeng Yao1,2, Shanshan Sun1,2, Xuan Zhou1,2, Wenyu Guo1,2, Lun Zhang3,4.   

Abstract

Insulin-like growth factor (IGF)-binding protein 2(IGFBP2), a key member of IGF family, has been reported as a notable oncogene in most human epithelium cancers. Increasing evidences suggested that IGFBP2 might be a candidate target of therapuetic potential by regulating key cancer metastasis and invasion-associated signaling networks, but there is still confusion about the mechanism on how IGFBP2 takes part in these processes. In this review, we summarized the current points of view that IGFBP2 functions in signaling pathways during tumorigenesis and tumor progression and discussed its potential clinical applications as a therapeutic target.

Entities:  

Keywords:  Biomarker; IGFBP2; Metastasis; Target therapy; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2015        PMID: 26662106     DOI: 10.1007/s13277-015-4561-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  91 in total

1.  Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins.

Authors:  Tomasz Sitar; Grzegorz M Popowicz; Igor Siwanowicz; Robert Huber; Tad A Holak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

Review 2.  β-Catenin in pluripotency: adhering to self-renewal or Wnting to differentiate?

Authors:  Galina S Sineva; Valery A Pospelov
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

3.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

4.  MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.

Authors:  Swadesh K Das; Sujit K Bhutia; Belal Azab; Timothy P Kegelman; Leyla Peachy; Prasanna K Santhekadur; Santanu Dasgupta; Rupesh Dash; Paul Dent; Steven Grant; Luni Emdad; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2012-12-10       Impact factor: 12.701

5.  The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton.

Authors:  Masanobu Kawai; Anne C Breggia; Victoria E DeMambro; Xinchun Shen; Ernesto Canalis; Mary L Bouxsein; Wesley G Beamer; David R Clemmons; Clifford J Rosen
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

6.  Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Elizabeth A Platz; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Alan Kristal; Howard L Parnes; Yuzhen Tao; William D Figg; M Scott Lucia; Ashraful Hoque; Ann W Hsing; Ian M Thompson; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2013-01-11

Review 7.  Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma.

Authors:  Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

8.  Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling.

Authors:  Xinchun Shen; Gang Xi; Laura A Maile; Christine Wai; Clifford J Rosen; David R Clemmons
Journal:  Mol Cell Biol       Date:  2012-08-06       Impact factor: 4.272

9.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.

Authors:  Lynette M Moore; Kristen M Holmes; Sarah M Smith; Ying Wu; Elena Tchougounova; Lene Uhrbom; Raymond Sawaya; Janet M Bruner; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-16       Impact factor: 11.205

10.  A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Authors:  I Brana; R Berger; T Golan; P Haluska; J Edenfield; J Fiorica; J Stephenson; L P Martin; S Westin; P Hanjani; M B Jones; K Almhanna; R M Wenham; D M Sullivan; W S Dalton; A Gunchenko; J D Cheng; L L Siu; J E Gray
Journal:  Br J Cancer       Date:  2014-10-07       Impact factor: 7.640

View more
  16 in total

1.  IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population.

Authors:  Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan
Journal:  Eur J Endocrinol       Date:  2019-02-01       Impact factor: 6.664

2.  Serum IGF-binding protein 2 (IGFBP-2) concentrations change early after gastric bypass bariatric surgery revealing a possible marker of leptin sensitivity in obese subjects.

Authors:  Giovanni Ceccarini; Caterina Pelosini; Federica Ferrari; Silvia Magno; Jacopo Vitti; Guido Salvetti; Carlo Moretto; Antonio Marioni; Piero Buccianti; Paolo Piaggi; Margherita Maffei; Ferruccio Santini
Journal:  Endocrine       Date:  2019-04-03       Impact factor: 3.633

3.  The Establishment of a Fast and Safe Orthotopic Colon Cancer Model Using a Tissue Adhesive Technique.

Authors:  Hong-Tao Hu; Zhe Wang; Myung Ji Kim; Lu-Shang Jiang; Shi-Jun Xu; Jaeyun Jung; Eunji Lee; Jung-Hoon Park; Nader Bakheet; Sung Hwan Yoon; Kun Yung Kim; Ho-Young Song; Suhwan Chang
Journal:  Cancer Res Treat       Date:  2020-12-15       Impact factor: 4.679

4.  ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2.

Authors:  Rozita Bagheri-Yarmand; Ramona Dadu; Lei Ye; Yaashmin Shiny Jebaraj; Jade A Martinez; Junsheng Ma; Rohinton S Tarapore; Joshua E Allen; Steven I Sherman; Michelle D Williams; Robert F Gagel
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

5.  IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.

Authors:  Maria Cristina De Martino; Peter M van Koetsveld; Richard A Feelders; Wouter W de Herder; Fadime Dogan; Joseph A M J L Janssen; Davine Hofste Op Bruinink; Claudia Pivonello; A Marlijn Waaijers; Annamaria Colao; Ronald R de Krijger; Rosario Pivonello; Leo J Hofland
Journal:  Endocrine       Date:  2019-03-05       Impact factor: 3.633

6.  A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.

Authors:  Xiaochao Tan; Lei Shi; Priyam Banerjee; Xin Liu; Hou-Fu Guo; Jiang Yu; Neus Bota-Rabassedas; B Leticia Rodriguez; Don L Gibbons; William K Russell; Chad J Creighton; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

7.  Targeting the mutant p53 secretome.

Authors:  Kartik Sehgal; David A Barbie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis.

Authors:  Chin-Sheng Hung; Chien-Yu Huang; Chia-Hwa Lee; Wei-Yu Chen; Ming-Te Huang; Po-Li Wei; Yu-Jia Chang
Journal:  Oncotarget       Date:  2017-07-05

9.  Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity.

Authors:  Huan Liu; Le Li; Hua Chen; Rui Kong; Shangha Pan; Jisheng Hu; Yongwei Wang; Yilong Li; Bei Sun
Journal:  Oncotarget       Date:  2017-06-27

10.  SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.

Authors:  Thomas Strub; Flavia G Ghiraldini; Saul Carcamo; Man Li; Aleksandra Wroblewska; Rajendra Singh; Matthew S Goldberg; Dan Hasson; Zichen Wang; Stuart J Gallagher; Peter Hersey; Avi Ma'ayan; Georgina V Long; Richard A Scolyer; Brian Brown; Bin Zheng; Emily Bernstein
Journal:  Nat Commun       Date:  2018-08-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.